An observational study in Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections and Antivirals, sponsored by University Hospital, Limoges. Completed at 16 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-15.
Sponsored by University Hospital, Limoges · Observational
Cytomegalovirus (CMV) is a ubiquitous herpesvirus that represent a major cause of morbidity in haematopoietic stem cell transplants (HSCT) recipients, mostly through reactivation of the recipient's virus.
If left untreated, 40 to 80% of patients will develop CMV infection, leading to CMV disease in 30 to 35 % patients, and associated with considerable morbi-mortality. Interstitial pneumonia is the most severe and specific manifestation, although CMV replication by itself has also indirect effects such as triggering graft versus host disease and increasing immunosuppression. The current burden of CMV infection increases by 25 to 30% the cost of the graft in France. This also includes the burden for refractory - infections, that represent up to 13% of recipients with CMV infection, including 3% of cases with virological resistance in France (data from the Reference Center cohorts).
Ganciclovir, or valganciclovir preemptive treatment, guided by CMV viral load follow-up allowed significant reduction of CMV disease to 2-6% but did not prevent CMV indirect effects. In addition, hematotoxicity can compromise post-transplant haematological reconstitution, thus preventing its use as prophylaxis in France. Foscarnet, iv-administered and nephrotoxic, remains less used. There is thus a high expectation from less toxic molecules for prophylaxis The development letermovir recently available for prophylaxis of CMV infection in high risk patients will modify the patients care and follow-up. This new molecule targeting CMV terminases (developed by Merck) was recently marketed in France (Jan 2020). However, the analysis of the letermovir phase III study and further publications show that the risk of emergence of resistance is low, but may occur in case of breakthrough and thus post AMM monitoring is required.
A "real-life" evaluation of these new molecules in terms of efficacy, emergence of resistance, tolerance and morbimortality related to CMV infection, is useful, to propose recommendations on management strategies, in particular for the most at-risk patients i.e. CMV-seropositive recipients. To this purpose, the National Reference Center in collaboration with the French Society for marrow graft and cell therapy (SFGMTC) set up a cohort of surveillance of allografted patients, receiving, in prevention or treatment, old and new molecules.
Cytomegalovirus (CMV) is a ubiquitous herpesvirus that represent a major cause of morbidity in haematopoietic stem cell transplants (HSCT) recipients, mostly through reactivation of the recipient's virus.
If left untreated, 40 to 80% of patients will develop CMV infection, leading to CMV disease in 30 to 35 % patients, and associated with considerable morbi-mortality. Interstitial pneumonia is the most severe and specific manifestation, although CMV replication by itself has also indirect effects such as triggering graft versus host disease and increasing immunosuppression. The current burden of CMV infection increases by 25 to 30% the cost of the graft in France. This also includes the burden for refractory - infections, that represent up to 13% of recipients with CMV infection, including 3% of cases with virological resistance in France (data from the Reference Center cohorts).
Ganciclovir, or valganciclovir preemptive treatment, guided by CMV viral load follow-up allowed significant reduction of CMV disease to 2-6% but did not prevent CMV indirect effects. In addition, hematotoxicity can compromise post-transplant haematological reconstitution, thus preventing its use as prophylaxis in France. Foscarnet, iv-administered and nephrotoxic, remains less used. There is thus a high expectation from less toxic molecules for prophylaxis The development letermovir recently available for prophylaxis of CMV infection in high risk patients will modify the patients care and follow-up. This new molecule targeting CMV terminases (developed by Merck) was recently marketed in France (Jan 2020). However, the analysis of the letermovir phase III study and further publications show that the risk of emergence of resistance is low, but may occur in case of breakthrough and thus post AMM monitoring is required.
A "real-life" evaluation of these new molecules in terms of efficacy, emergence of resistance, tolerance and morbimortality related to CMV infection, is useful, to propose recommendations on management strategies, in particular for the most at-risk patients i.e. CMV-seropositive recipients. To this purpose, the National Reference Center in collaboration with the French Society for marrow graft and cell therapy (SFGMTC) set up a cohort of surveillance of allografted patients, receiving, in prevention or treatment, old and new molecules.
359 studies on the registry are indexed under Cytomegalovirus Infections; 59 are open to participants now.
This study's enrollment of 400 is above the median of 150 across 97 observational studies indexed under Cytomegalovirus Infections.
Browse Cytomegalovirus Infections studies →University Hospital, Limoges is the lead sponsor of 255 studies on the registry; 36 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Candidate (adult) for an allograft of hematopoietic stem cells for which a decision of transplant is made and willing to participate in the cohort.
Exclusion Criteria :
The National Reference Center (CNR) for cytomegalovirus with the French Society for Medullary Transplantation and Cell Therapy (SFGM-TC) has set up a surveillance cohort of allografted patients (NAViRe cohort) receiving, as prevention or treatment, Anti-Cytomegalovirus (Anti-CMV) molecules, "new or less recent", thus allowing the development of a new observatory evaluating in real life the potentials of these drugs in terms of efficacy, emergence of resistance, tolerance and morbidity and mortality associated with CMV infection.This work is useful to propose recommendations on management strategies, in particular for the most at-risk patients i.e. CMV-seropositive recipients and allows the emergence of an real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients.
Other: Real-life observatory of efficacy and resistance to anti CMV molecules in stem cell recipients
Signing of consent at the time of the pre-transplant consultation (1 month before grafting). Inclusion of patients during conditioning (around D-8 of transplantation). Samples related to the cohort:one blood sample from the donor (only familial donors) for genetic SNPs analysis. 5 samples: D-8, D20, D100, D200 (+/-10 days), 1 year : 1 tube of 7ml of whole blood on EDTA: Biobanking of whole blood for genetic SNPs analysis (D-8) of specific transporters for GCV, and of plasma for TTV viral load at all times. In routine care:samples taken in the event of a therapeutic escape (2 x 7 ml EDTA tubes, for resistance genotype, and ganciclovir dosage, 3 x 1 ml for Quantiferon CMV, according to CNR Herpesvirus recommendations. 1 x Paxgene tube (2.5 ml) for subsequent CMV genomic and transcriptomic studies. Cell preservation plasma and whole blood for biocollection (2 tubes EDTA de 7ml). Samples stored by the centers' virology laboratories are periodically sent to the CNR for analysis.
CMV infection according to criteria defined by the European EBMT group (Ljungman et al., 2017).
CMV detection (CMV DNAemia or antigen detection) in any body fluid or tissue specimen
Time frame: between Day-30 and Day -8
CMV infection according to criteria defined by the European EBMT group (Ljungman et al., 2017).
CMV detection (CMV DNAemia or antigen detection) in any body fluid or tissue specimen
Time frame: between Day-8 and Day 0
CMV infection according to criteria defined by the European EBMT group (Ljungman et al., 2017).
CMV detection (CMV DNAemia or antigen detection) in any body fluid or tissue specimen
Time frame: at Day20
CMV infection according to criteria defined by the European EBMT group (Ljungman et al., 2017).
CMV detection (CMV DNAemia or antigen detection) in any body fluid or tissue specimen
Time frame: at Day100
CMV infection according to criteria defined by the European EBMT group (Ljungman et al., 2017).
CMV detection (CMV DNAemia or antigen detection) in any body fluid or tissue specimen
Time frame: at Day 200 (Month 6)
CMV infection according to criteria defined by the European EBMT group (Ljungman et al., 2017).
CMV detection (CMV DNAemia or antigen detection) in any body fluid or tissue specimen
Time frame: Month12
CMV infection according to criteria defined by the European EBMT group (Ljungman et al., 2017).
CMV detection (CMV DNAemia or antigen detection) in any body fluid or tissue specimen
Time frame: Month24
Uses of anti-CMV molecules : preemptive treatment
% of patients having received preemptive treatment
Time frame: at Day200
Uses of anti-CMV molecules : prophylaxis
% of patients having received prophylaxis
Time frame: at Day200
Uses of anti-CMV molecules : curative treatment
% of patients having received curative treatment
Time frame: at Day200
Uses of anti-CMV molecules
Cumulative duration of exposure (number of day) for each drug administered
Time frame: at Day200
Uses of anti-CMV molecules : preemptive treatment
% of patients having received preemptive treatment
Time frame: at Month12
Uses of anti-CMV molecules : prophylaxis
% of patients having received prophylaxis
Time frame: at Month12
Uses of anti-CMV molecules : curative treatment
% of patients having received curative treatment
Time frame: at Month12
Uses of anti-CMV molecules
Cumulative duration of exposure (number of day) for each drug administered
Time frame: at Month12
Uses of anti-CMV molecules : preemptive treatment
% of patients having received preemptive treatment
Time frame: at Month24
Uses of anti-CMV molecules : prophylaxis
% of patients having received prophylaxis
Time frame: at Month24
Uses of anti-CMV molecules : curative treatment
% of patients having received curative treatment
Time frame: at Month24
Uses of anti-CMV molecules
Cumulative duration of exposure (number of day) for each drug administered
Time frame: at Month24
Incidence of the non-response and resistance to antivirals with risk factors associated (virological, pharmacological, immunological). Criteria recently published by Chemaly et al. CID 2018 will be used to classify cases in
Criteria recently published by Chemaly et al. CID 2018 will be used to classify cases in : * Refractory CMV infection CMV viremia that increases after at least 2 wk of appropriately dosed antiviral therapy. * Probable refractory CMV infection : persistent viral load after at least 2 wk of appropriately dosed antiviral therapy. * Refractory CMV end organ disease : worsening in signs and symptoms or progression into end-organ disease after at least 2 wk of appropriately dosed antiviral therapy. * Probable refractory CMV end-organ disease : lack of improvement in signs and symptoms after at least 2 wk of appropriately dosed antiviral drugs. * Antiviral drug resistance : viral genetic alteration that decreases susceptibility to one or more antiviral drugs. Resistance : presence of a resistance-related mutation by resistance genotyping of UL97, UL54, UL56, UL89, UL27 genes, carried out or validated by the Limoges Herpesviruses reference laboratory. In blood or any other sample.
Time frame: at Month12
Incidence of the non-response and resistance to antivirals with risk factors associated (virological, pharmacological, immunological). Criteria recently published by Chemaly et al. CID 2018 will be used to classify cases in
Criteria recently published by Chemaly et al. CID 2018 will be used to classify cases in : * Refractory CMV infection CMV viremia that increases after at least 2 wk of appropriately dosed antiviral therapy. * Probable refractory CMV infection : persistent viral load after at least 2 wk of appropriately dosed antiviral therapy. * Refractory CMV end organ disease : worsening in signs and symptoms or progression into end-organ disease after at least 2 wk of appropriately dosed antiviral therapy. * Probable refractory CMV end-organ disease : lack of improvement in signs and symptoms after at least 2 wk of appropriately dosed antiviral drugs. * Antiviral drug resistance : viral genetic alteration that decreases susceptibility to one or more antiviral drugs. Resistance : presence of a resistance-related mutation by resistance genotyping of UL97, UL54, UL56, UL89, UL27 genes, carried out or validated by the Limoges Herpesviruses reference laboratory. In blood or any other sample.
Time frame: at Month24
Adverse effects leading to interruption of treatment
Incidence of treatment emergent adverse event as assessed by interruption of treatment
Time frame: at Month12
Adverse effects leading to interruption of treatment
Incidence of treatment emergent adverse event as assessed by interruption of treatment
Time frame: at Month24
CMV related mortality
Number of patients who died from CMV related desease
Time frame: at Month12
CMV related mortality
Number of patients who died from CMV related desease
Time frame: at Month24
CMV associated morbidity : delay engraftment
number of days bettwen graft and engraftment
Time frame: at Month12
CMV associated morbidity : GVHD
Incidence of GVHD
Time frame: at Month12
CMV associated morbidity : CMV infection/disease
Incidence of CMV infection/disease (infection or disease will be combined to report this outcome). CMV infection : positive diagnostic test (CMV culture, antigen detection or CMV PCR), in any body fluid or tissue, in the absence of symptoms. CMV disease : CMV infection associated with end-organ disease (clinical signs and oriented virological diagnosis).
Time frame: at Month12
CMV associated morbidity : delay engraftment
number of days bettwen graft and engraftment
Time frame: at Month24
CMV associated morbidity : GVHD
Incidence of GVHD
Time frame: at Month24
CMV associated morbidity : CMV infection/disease
Incidence of CMV infection/disease (infection or disease will be combined to report this outcome). CMV infection : positive diagnostic test (CMV culture, antigen detection or CMV PCR), in any body fluid or tissue, in the absence of symptoms. CMV disease : CMV infection associated with end-organ disease (clinical signs and oriented virological diagnosis).
Time frame: at Month24
Plan to share: No
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Limoges